Evaluation of beta-absorbed fractions in a mouse model for90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides

William H. Miller, Christine Hartmann-Siantar, Darrell Fisher, Marie Anne Descalle, Tom Daly, Joerg Lehmann, Michael R. Lewis, Timothy Hoffman, Jeff Smith, Peter D. Situ, Wynn A. Volkert

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Several short-lived, high-energy beta emitters are being proposed as the radionuclide components for molecular-targeted potential cancer therapeutic agents. The laboratory mice used to determine the efficacy of these new agents have organs that are relatively small compared to the ranges of these high-energy particles. The dosimelry model developed by Hui et al. was extended to provide realistic beta-dose estimates for organs in mice that received therapeutic radiopharmaceuticals containing 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu. Major organs in this model included the liver, spleen, kidneys, lungs, heart, stomach, small and large bowel, thyroid, pancreas, bone, marrow, carcass, and a 0.025-g tumor. The study as reported in this paper verifies their results for 90Y and extends them by using their organ geometry factors combined with newly calculated organ self-absorbed fractions from PEREGRINE and MCNP. PEREGRINE and MCNP agree to within 8% for the worst-case organ with average differences (averaged over all organs) decreasing from 5% for 90Y to 1% for 177Lu. When used with typical biodistribution data, the three different models predict doses that are in agreement to within 5% for the worst-case organ. The beta-absorbed fractions and cross-organ-deposited energy provided in this paper can be used by researchers to predict mouse-organ doses and should contribute to an improved understanding of the relationship between dose and radiation toxicity in mouse models where use of these isotopes is favorable.

Original languageEnglish (US)
Pages (from-to)436-449
Number of pages14
JournalCancer Biotherapy and Radiopharmaceuticals
Volume20
Issue number4
DOIs
StatePublished - 2005

Fingerprint

Radioisotopes
Radiopharmaceuticals
Isotopes
Pancreas
Neoplasms
Stomach
Thyroid Gland
Spleen
Bone Marrow
Research Personnel
Radiation
Kidney
Lung
Liver
Therapeutics

Keywords

  • Pm
  • Ho
  • Lu
  • Re
  • Cu
  • Y
  • Beta-emitter dosimetry
  • MCNP
  • Medical Internal Radiation Dose (MIRD) estimates
  • Molecular targeted radionuclide therapy
  • Mouse model
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Miller, W. H., Hartmann-Siantar, C., Fisher, D., Descalle, M. A., Daly, T., Lehmann, J., ... Volkert, W. A. (2005). Evaluation of beta-absorbed fractions in a mouse model for90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides. Cancer Biotherapy and Radiopharmaceuticals, 20(4), 436-449. https://doi.org/10.1089/cbr.2005.20.436

Evaluation of beta-absorbed fractions in a mouse model for90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides. / Miller, William H.; Hartmann-Siantar, Christine; Fisher, Darrell; Descalle, Marie Anne; Daly, Tom; Lehmann, Joerg; Lewis, Michael R.; Hoffman, Timothy; Smith, Jeff; Situ, Peter D.; Volkert, Wynn A.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 20, No. 4, 2005, p. 436-449.

Research output: Contribution to journalArticle

Miller, WH, Hartmann-Siantar, C, Fisher, D, Descalle, MA, Daly, T, Lehmann, J, Lewis, MR, Hoffman, T, Smith, J, Situ, PD & Volkert, WA 2005, 'Evaluation of beta-absorbed fractions in a mouse model for90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides', Cancer Biotherapy and Radiopharmaceuticals, vol. 20, no. 4, pp. 436-449. https://doi.org/10.1089/cbr.2005.20.436
Miller, William H. ; Hartmann-Siantar, Christine ; Fisher, Darrell ; Descalle, Marie Anne ; Daly, Tom ; Lehmann, Joerg ; Lewis, Michael R. ; Hoffman, Timothy ; Smith, Jeff ; Situ, Peter D. ; Volkert, Wynn A. / Evaluation of beta-absorbed fractions in a mouse model for90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides. In: Cancer Biotherapy and Radiopharmaceuticals. 2005 ; Vol. 20, No. 4. pp. 436-449.
@article{0b20ee9e9d414f9d8a006145e9ea3e38,
title = "Evaluation of beta-absorbed fractions in a mouse model for90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides",
abstract = "Several short-lived, high-energy beta emitters are being proposed as the radionuclide components for molecular-targeted potential cancer therapeutic agents. The laboratory mice used to determine the efficacy of these new agents have organs that are relatively small compared to the ranges of these high-energy particles. The dosimelry model developed by Hui et al. was extended to provide realistic beta-dose estimates for organs in mice that received therapeutic radiopharmaceuticals containing 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu. Major organs in this model included the liver, spleen, kidneys, lungs, heart, stomach, small and large bowel, thyroid, pancreas, bone, marrow, carcass, and a 0.025-g tumor. The study as reported in this paper verifies their results for 90Y and extends them by using their organ geometry factors combined with newly calculated organ self-absorbed fractions from PEREGRINE and MCNP. PEREGRINE and MCNP agree to within 8{\%} for the worst-case organ with average differences (averaged over all organs) decreasing from 5{\%} for 90Y to 1{\%} for 177Lu. When used with typical biodistribution data, the three different models predict doses that are in agreement to within 5{\%} for the worst-case organ. The beta-absorbed fractions and cross-organ-deposited energy provided in this paper can be used by researchers to predict mouse-organ doses and should contribute to an improved understanding of the relationship between dose and radiation toxicity in mouse models where use of these isotopes is favorable.",
keywords = "Pm, Ho, Lu, Re, Cu, Y, Beta-emitter dosimetry, MCNP, Medical Internal Radiation Dose (MIRD) estimates, Molecular targeted radionuclide therapy, Mouse model, Radioimmunotherapy",
author = "Miller, {William H.} and Christine Hartmann-Siantar and Darrell Fisher and Descalle, {Marie Anne} and Tom Daly and Joerg Lehmann and Lewis, {Michael R.} and Timothy Hoffman and Jeff Smith and Situ, {Peter D.} and Volkert, {Wynn A.}",
year = "2005",
doi = "10.1089/cbr.2005.20.436",
language = "English (US)",
volume = "20",
pages = "436--449",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Evaluation of beta-absorbed fractions in a mouse model for90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides

AU - Miller, William H.

AU - Hartmann-Siantar, Christine

AU - Fisher, Darrell

AU - Descalle, Marie Anne

AU - Daly, Tom

AU - Lehmann, Joerg

AU - Lewis, Michael R.

AU - Hoffman, Timothy

AU - Smith, Jeff

AU - Situ, Peter D.

AU - Volkert, Wynn A.

PY - 2005

Y1 - 2005

N2 - Several short-lived, high-energy beta emitters are being proposed as the radionuclide components for molecular-targeted potential cancer therapeutic agents. The laboratory mice used to determine the efficacy of these new agents have organs that are relatively small compared to the ranges of these high-energy particles. The dosimelry model developed by Hui et al. was extended to provide realistic beta-dose estimates for organs in mice that received therapeutic radiopharmaceuticals containing 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu. Major organs in this model included the liver, spleen, kidneys, lungs, heart, stomach, small and large bowel, thyroid, pancreas, bone, marrow, carcass, and a 0.025-g tumor. The study as reported in this paper verifies their results for 90Y and extends them by using their organ geometry factors combined with newly calculated organ self-absorbed fractions from PEREGRINE and MCNP. PEREGRINE and MCNP agree to within 8% for the worst-case organ with average differences (averaged over all organs) decreasing from 5% for 90Y to 1% for 177Lu. When used with typical biodistribution data, the three different models predict doses that are in agreement to within 5% for the worst-case organ. The beta-absorbed fractions and cross-organ-deposited energy provided in this paper can be used by researchers to predict mouse-organ doses and should contribute to an improved understanding of the relationship between dose and radiation toxicity in mouse models where use of these isotopes is favorable.

AB - Several short-lived, high-energy beta emitters are being proposed as the radionuclide components for molecular-targeted potential cancer therapeutic agents. The laboratory mice used to determine the efficacy of these new agents have organs that are relatively small compared to the ranges of these high-energy particles. The dosimelry model developed by Hui et al. was extended to provide realistic beta-dose estimates for organs in mice that received therapeutic radiopharmaceuticals containing 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu. Major organs in this model included the liver, spleen, kidneys, lungs, heart, stomach, small and large bowel, thyroid, pancreas, bone, marrow, carcass, and a 0.025-g tumor. The study as reported in this paper verifies their results for 90Y and extends them by using their organ geometry factors combined with newly calculated organ self-absorbed fractions from PEREGRINE and MCNP. PEREGRINE and MCNP agree to within 8% for the worst-case organ with average differences (averaged over all organs) decreasing from 5% for 90Y to 1% for 177Lu. When used with typical biodistribution data, the three different models predict doses that are in agreement to within 5% for the worst-case organ. The beta-absorbed fractions and cross-organ-deposited energy provided in this paper can be used by researchers to predict mouse-organ doses and should contribute to an improved understanding of the relationship between dose and radiation toxicity in mouse models where use of these isotopes is favorable.

KW - Pm

KW - Ho

KW - Lu

KW - Re

KW - Cu

KW - Y

KW - Beta-emitter dosimetry

KW - MCNP

KW - Medical Internal Radiation Dose (MIRD) estimates

KW - Molecular targeted radionuclide therapy

KW - Mouse model

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=24044535093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044535093&partnerID=8YFLogxK

U2 - 10.1089/cbr.2005.20.436

DO - 10.1089/cbr.2005.20.436

M3 - Article

C2 - 16114992

AN - SCOPUS:24044535093

VL - 20

SP - 436

EP - 449

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 4

ER -